Treatment of aggressive and symptomatic rearranged during transfection (RET) mutant medullary thyroid cancer in patients aged ≥5 years with unresectable locally advanced or metastatic disease. NHSE commissioned.
Red Drug Classifications
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
